CD8A and neoplasm: All these results suggest that Ad-E7 used in combination therapy confers an ability to the immune system to limit tumor growth by lowering Treg and MDSC levels while minimizing tumor size via invasion of CD8 T-cells and their corresponding release of interferon gamma.